Scientific Advisory Board
Howard A. “Skip” Burris, MD, FACP, FASCO
Dr. Burris serves as President and Chief Medical Officer of Sarah Cannon, as well as the Executive Director, Drug Development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.
Dr. Burris’ clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.​
​
Dr. Burris served as the elected president of ASCO in 2019-2020. He currently serves as the Chair of the Society’s Board and also as the Chair of the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.
​​
Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.
Charles (Chuck) Karan, Ph.D.
Dr. Karan is the scientific director for the High-Throughput Screening Facility at the JP Sulzberger Columbia Genome Center. In this role, he assists researchers at Columbia and from other institutions to develop and implement high-throughput screening protocols tailored to the goals of individual research projects. He also manages all operations of the HTS facility.
Karan completed his PhD in 1998 at the University of Rochester, where he studied organic chemistry under the supervision of Professor Benjamin L. Miller. In Rochester he led a project that developed new ways to discover ligands for biological targets and worked with a team on developing and optimizing metal catalyzed reactions.
He later pursued postdoctoral research at Harvard University Medical Center's Institute of Chemistry and Cellular Biology (ICCB) under the supervision of Dr. John A. Tallerico. At the ICCB Charles worked as a member of several multidisciplinary teams to overcome obstacles in chemistry and biology.
After his postdoctoral research, Karan became manager of the High-Throughput Screening Resource Center at the Rockefeller University, where he was responsible for all aspects of running the center, including both scientific and budgetary concerns. Under his leadership the center saw a major expansion in space and instrumentation.
In 2009 Karan joined Therasis, a startup biotechnology company, as the head of high-throughput screening. His responsibilities included all activities related to high-throughput screening and laboratory automation. He was eventually promoted to director of technology, overseeing all scientific aspects of the company.
Michael Matiland, M.D.
Dr. Matiland is currently the Medical Lead, Intellia Therapeutics, Inc. Physician Scientist, ASCO Cancer Research Committee.
For 20 years, as a board-certified physician in both Medical Oncology and Clinical Pharmacology Dr. Maitland led academic research programs with continuous NIH funding to employ new technologies to improve the development of safe and effective treatments for cancer.
His clinical focus has been on the conduct of early phase clinical trials and care of patients with metastatic solid tumors. Past national service responsibilities included Director of the American Board of Clinical Pharmacology, and member of the National Cancer Institute Investigational Drug Steering Committee. Recently,
He continues to maintain academic roles as Professor of Medicine at the University of Virginia and as a member of the University of Virginia Comprehensive Cancer Center.
Diane Mould, Ph.D.
Dr. Diane Mould obtained her bachelor’s degree in 1984 and her Ph.D. in 1989. She spent 30+ years as a pharmacokineticist in industry where she specialized in population pharmacokinetic / pharmacodynamic modeling. She has conducted population PK/PD analyses of hematopoietic agents, monoclonal antibodies, anti-cancer and anti-viral agents, antipsychotic, cardiovascular, and sedative/hypnotic agents.
Dr. Mould is president of Projections Research Inc., a consulting company offering pharmacokinetic and pharmacometric services. She is also the founder of Baysient LLC, a company that develops systems to individualize doses of drugs that are difficult to manage. She has published 110 peer-reviewed articles, 19 book chapters and was a co-editor of one textbook. She has made 134 national and international presentations and presented 6 podium sessions on advanced modeling and simulation approaches.
She is an adjunct professor at the University of Rhode Island (URI), OSU, and the University of Florida, and teaches an annual class on disease progression modeling at the National Institutes of Health. Dr Mould taught 12 courses (OSU, URI and SUNY Buffalo) on specialized aspects of population pharmacokinetic and dynamic modeling. She is a member of the editorial board for Journal of Pharmacokinetics and Pharmacodynamics, Clinical Pharmacology and Therapeutics, and is on the Scientific Advisory Board for Clinical Pharmacology and Therapeutics Pharmacometrics and Systems Pharmacology. She is a Fellow of the American College of Clinical Pharmacology and a Fellow of the American Association of Pharmaceutical Sciences.